Media stories about SciClone Pharmaceuticals (NASDAQ:SCLN) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. SciClone Pharmaceuticals earned a news sentiment score of 0.16 on Accern’s scale. Accern also gave media stories about the specialty pharmaceutical company an impact score of 46.1523035931563 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

These are some of the news articles that may have effected Accern Sentiment’s scoring:

SciClone Pharmaceuticals (NASDAQ SCLN) remained flat at $11.15 during trading on Wednesday. The company’s stock had a trading volume of 2,224,627 shares. The company’s 50 day moving average is $11.10 and its 200 day moving average is $10.55. The company has a market capitalization of $581.93 million, a P/E ratio of 13.75 and a beta of 1.72. SciClone Pharmaceuticals has a 52-week low of $8.55 and a 52-week high of $11.43.

SciClone Pharmaceuticals (NASDAQ:SCLN) last posted its quarterly earnings data on Wednesday, August 9th. The specialty pharmaceutical company reported $0.26 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.24 by $0.02. The firm had revenue of $44.52 million for the quarter. SciClone Pharmaceuticals had a return on equity of 21.10% and a net margin of 25.18%. Analysts predict that SciClone Pharmaceuticals will post $0.94 EPS for the current year.

In other SciClone Pharmaceuticals news, CEO Hong Zhao sold 30,000 shares of the company’s stock in a transaction dated Wednesday, August 16th. The stock was sold at an average price of $11.00, for a total transaction of $330,000.00. Following the sale, the chief executive officer now owns 30,000 shares in the company, valued at approximately $330,000. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Lan Xie sold 10,000 shares of the company’s stock in a transaction dated Wednesday, August 16th. The stock was sold at an average price of $11.00, for a total value of $110,000.00. Following the sale, the vice president now owns 10,000 shares in the company, valued at approximately $110,000. The disclosure for this sale can be found here. 5.16% of the stock is currently owned by insiders.

TRADEMARK VIOLATION WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact SciClone Pharmaceuticals (SCLN) Stock Price” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/10/18/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-sciclone-pharmaceuticals-scln-stock-price.html.

About SciClone Pharmaceuticals

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

Insider Buying and Selling by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)

Receive News & Stock Ratings for SciClone Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.